Skip to main content
. 2025 Jan 2;11(1):e189. doi: 10.1097/JW9.0000000000000189

Fig. 7.

Fig. 7.

Dermatologists’ level of comfort with TNFi treatment in women aged 18–45 years with PSO. “How comfortable are you in prescribing TNFi therapy for the following types of PSO patients?.” Dermatologists from Japan were asked to disregard patients with psoriatic arthritis when responding. These data do not add up to 100% due to a rounding error. PSO, psoriasis; TNFi, tumor necrosis factor inhibitors.